Evaxion A (EVAX) Cash from Financing Activities (2020 - 2022)
Evaxion A's (EVAX) quarterly Cash from Financing Activities came in at -$300000.0 in Q2 2022, down 101.19% YoY from $25.2 million in Q2 2021, and down 103.88% on a QoQ basis from $7.7 million in Q1 2022.
Evaxion A (EVAX) Cash from Financing Activities (2020 - 2022) Analysis & Trends
Evaxion A (EVAX) has 3 years of Cash from Financing Activities data on file, last reported at -$300000.0 in Q2 2022.
- Quarterly Cash from Financing Activities fell 101.19% year-over-year to -$300000.0 in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $57.8 million (up 1.64% YoY) and the FY2025 annual result came in at $22.4 million, up 70.69% from the prior year.
- Cash from Financing Activities retreated to -$300000.0 in Q2 2022, from $7.7 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $25.3 million in Q1 2021 to a low of -$300000.0 in Q2 2022.
- A 3-year average of $11.2 million and a median of $7.1 million in 2020 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2021 — Cash from Financing Activities jumped 140388.89% — and 2022, when it plunged 101.19%.
- Tracing EVAX's Cash from Financing Activities over 3 years: stood at $6.4 million in 2020, then soared by 290.38% to $25.2 million in 2021, then sank by 101.19% to -$300000.0 in 2022.
- The last three Cash from Financing Activities figures came in at -$300000.0 (Q2 2022), $7.7 million (Q1 2022), and $25.2 million (Q3 2021), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | -300,000.00 |
| Jun 30, 2022 | -300,000.00 |
| Mar 31, 2022 | 7.74 Mn |
| Mar 31, 2022 | 7.74 Mn |
| Sep 30, 2021 | 25.15 Mn |
| Sep 30, 2021 | 25.15 Mn |
| Jun 30, 2021 | 25.22 Mn |
| Jun 30, 2021 | 25.22 Mn |
| Mar 31, 2021 | 25.25 Mn |
| Mar 31, 2021 | 25.25 Mn |
| Sep 30, 2020 | 6.44 Mn |
| Sep 30, 2020 | 6.44 Mn |
| Jun 30, 2020 | -36,000.00 |
| Jun 30, 2020 | -36,000.00 |
| Mar 31, 2020 | -18,000.00 |
| Mar 31, 2020 | -18,000.00 |